文献速递浆细胞疾病

监测残留浆细胞遗传学架构揭示多发性骨髓瘤治疗诱导的克隆选择

Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma.
PubMed 文献 · Leukemia · 2019-10-07

该研究对193例诊断时至少有一种细胞遗传学异常的多发性骨髓瘤患者,在诊断和治疗后样本中行间期荧光原位杂交分析。结果显示63%患者残留浆细胞持续存在细胞遗传学异常,即使MRD阴性患者中也有44%可检出;残留浆细胞无细胞遗传学异常与生存延长相关,治疗诱导的克隆选择显著影响生存(HR=4.0;P<0.001)。

要点

  • 残留浆细胞持续存在细胞遗传学异常者占63%,MRD阴性者中44%仍可检出。
  • 残留浆细胞无细胞遗传学异常与生存延长相关,不受MRD状态影响。
  • 治疗诱导的克隆选择显著影响生存(HR=4.0;P<0.001)。

核心结论

  • 重复评估残留浆细胞细胞遗传学可作为MRD检测的补充工具,并有助于理解临床反应和克隆演化。

研究设计与样本

  • 研究纳入193例诊断时至少有一种细胞遗传学异常的多发性骨髓瘤患者,对配对诊断和治疗后样本行间期荧光原位杂交分析。

主要发现

  • 63%患者残留浆细胞持续存在细胞遗传学异常,28/63(44%)MRD阴性(<10-4)患者中仍可检出。
  • 残留浆细胞无细胞遗传学异常与生存延长相关,无论MRD状态如何。
  • 根据特定细胞遗传学异常克隆大小的变化,患者被聚类为五组,反映治疗压力下不同的克隆选择模式。
  • 治疗诱导的克隆选择显著影响生存(HR=4.0;P<0.001)。
  • 多数患者复发时纵向细胞遗传学呈现序贯动态变化,残留浆细胞遗传学架构可在一定程度上预测复发时的演化模式。

临床怎么用

  • 对多发性骨髓瘤患者可考虑重复评估残留浆细胞细胞遗传学,作为MRD检测的补充以更好评估临床反应和克隆演化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent attempts have focused on identifying fewer magnitude of minimal residual disease (MRD) rather than exploring the biological and genetic features of the residual plasma cells (PCs). Here, a cohort of 193 patients with at least one cytogenetic abnormalities (CA) at diagnosis were analyzed, and interphase fluorescence in situ hybridization (iFISH) analyses were performed in patient-paired diagnostic and posttherapy samples. Persistent CA in residual PCs were observed for the majority of patients (63%), even detectable in 28/63 (44%) patients with MRD negativity (<10-4). The absence of CA in residual PCs was associated with prolonged survival regardless of MRD status. According to the change of the clonal size of specific CA, patients were clustered into five groups, reflecting different patterns of clone selection under therapy pressure. Therapy-induced clonal selection exerted a significant impact on survival (HR = 4.0; P < 0.001). According to the longitudinal cytogenetic studies at relapse, sequential cytogenetic dynamics were observed in most patients, and cytogenetic architecture of residual PCs could to some extent predict the evolutional pattern at relapse. Collectively, the repeat cytogenetic evaluation in residual PCs could not only serves as a good complementary tool for MRD detection, but also provides a better understanding of clinical response and clonal evolution.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. An G, Yan Y, Xu Y, et al. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. Leukemia. 2019. PMID: 31591469. doi:10.1038/s41375-019-0590-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。